 |
|
Effectiveness of a Mass Immunization Campaign Against Serogroup C Meningococcal Disease in Quebec
Philippe De Wals, PhD;
Gaston De Serres, PhD;
Théophile Niyonsenga, PhD
JAMA. 2001;285:177-181.
Context An outbreak of meningococcal disease in Quebec province prompted a mass immunization program. The impact of this campaign on the epidemiology of meningococcal disease has not been studied.
Objectives To study the impact of a mass immunization campaign using polysaccharide vaccine on the epidemiology of meningococcal disease (MCD) and to assess serogroup C vaccine effectiveness (VE).
Design, Setting, and Subjects Analysis of MCD cases reported in Quebec from 1990 to 1998, before and after the mass immunization campaign was conducted during the winter of 1992-1993, when 84% of residents aged 6 months to 20 years (the target population, approximately 1.9 million individuals) were vaccinated.
Main Outcome Measures Incidence of MCD in 1990-1998; incidence of culture-proven serogroup C MCD between April 1, 1993, and March 31, 1998, compared among vaccinated and unvaccinated persons in the target population.
Results The incidence of serogroup C disease decreased after the mass immunization campaign, from 1.4 per 100 000 in 1990-1992 to 0.3 per 100 000 in 1993-1998, and the overall incidence of other serogroups remained stable at 0.7 per 100 000, with a small increase in the proportion of cases caused by serogroup Y (P = .009). Protection from serogroup C MCD was indicated in the first 2 years after vaccine administration (VE, 65%; 95% confidence interval [CI], 20%-84%), but not in the next 3 years (VE, 0%; 95% CI, -5% to 65%). Vaccine effectiveness was strongly related to age at vaccination: 83% (95% CI, 39%-96%) for ages 15 through 20 years, 75% (95% CI, - 17% to 93%) for ages 10 through 14 years, and 41% (95% CI, -106% to 79%) for ages 2 through 9 years. There was no evidence of protection in children younger than 2 years; all 8 MCD cases in this age group occurred in vaccinees.
Conclusions Serogroup C polysaccharide vaccine is effective for controlling outbreaks in teenaged individuals but should not be used in children younger than 2 years. The mass campaign did not induce significant serogroup switching.
Author Affiliations: Department of Community Health Sciences, University of Sherbrooke and Clinical Research Center, Sherbrooke University Hospital Center, Sherbrooke, Quebec (Drs De Wals and Niyonsenga); and Public Health Research Unit, Quebec University Hospital Center, Laval University, Quebec (Dr De Serres).
RELATED ARTICLE
January 10, 2001
JAMA. 2001;285(2):229-230.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
Snape et al.
BMJ 2008;336:1487-1491.
ABSTRACT
| FULL TEXT
Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations
Fombonne et al.
Pediatrics 2006;118:e139-e150.
ABSTRACT
| FULL TEXT
Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age
Al-Mazrou et al.
Infect. Immun. 2005;73:2932-2939.
ABSTRACT
| FULL TEXT
Effectiveness of a Mass Immunization Campaign Using Serogroup C Meningococcal Conjugate Vaccine
De Wals et al.
JAMA 2004;292:2491-2494.
ABSTRACT
| FULL TEXT
Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway
Yazdankhah et al.
J. Clin. Microbiol. 2004;42:5146-5153.
ABSTRACT
| FULL TEXT
Phenotypic and Genetic Characterization of a Unique Variant of Serogroup C ET-15 Meningococci (with the Antigenic Formula C:2a:P1.7,1) Causing Invasive Meningococcal Disease in Quebec, Canada
Tsang et al.
J. Clin. Microbiol. 2004;42:1460-1465.
ABSTRACT
| FULL TEXT
Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England
Andrews et al.
CVI 2003;10:780-786.
ABSTRACT
| FULL TEXT
Age-Related Disparity in Functional Activities of Human Group C Serum Anticapsular Antibodies Elicited by Meningococcal Polysaccharide Vaccine
Harris et al.
Infect. Immun. 2003;71:275-286.
ABSTRACT
| FULL TEXT
Falik
AAP News 2001;18:144-144.
FULL TEXT
Immunogenicity of Bivalent AC Polysaccharide Meningococcal Vaccine in Children Aged 6 Through 24 Months
Lebel et al.
JAMA 2001;285:1578-1579.
FULL TEXT
|
